Ponatinib

CHF 72.00
In stock
SYN-1116-M0011 mgCHF 72.00
SYN-1116-M0055 mgCHF 108.00
SYN-1116-M01010 mgCHF 132.00
SYN-1116-M05050 mgCHF 437.00
SYN-1116-M100100 mgCHF 724.00
 
More Information
Product Details
Synonyms AP24534
Product Type Chemical
Properties
Formula C29H27F3N6O
MW 532.6
CAS 943319-70-8
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: Abl - BCR - FGFR | Kinase Group: PTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key PHXJVRSECIGDHY-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Ponatinib is a potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC(50) values of 0.37, 1.1, 1.5, 2.2 and 5.4nM respectively.
Product References
  1. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance: T. O'Hare, et al.; Cancer Cell 16, 401 (2009)
  2. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant: W.S. Huang, et al.; J. Med. Chem. 53, 4701 (2010)
  3. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies: J.M. Gozgit, et al.; Mol. Cancer Ther. 10, 1028 (2011)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.